For instance, a trispecific killer engager (TriKE) targeting CLEC12A/CD16/IL-15 uses innate immune mechanisms to kill AML cells via NK activation and IL-15-driven proliferation [54]. This evidence concerns the gene IL15 and acute myeloid leukemia.